The study investigates the immunogenicity of a third dose of mRNA COVID-19 vaccines (Moderna and Pfizer-BioNTech) in kidney transplant recipients who exhibited inadequate antibody responses after two doses. Given the increasing recognition of vulnerable populations, such as transplant recipients, this research addresses a critical gap in COVID-19 vaccination strategies. The results could inform future vaccine recommendations and potentially expand market opportunities for mRNA vaccine manufacturers. The competitive landscape includes ongoing studies by other institutions focusing on similar populations, which may influence market positioning and pricing strategies. Diligence should consider the regulatory landscape and potential for expanded indications based on study outcomes.